NUWELLIS INC (NUWE)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.80+1.52%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Reduce operating losses toward breakeven: Operating loss not reported.
Nuwellis bought Rendiatech to grow kidney monitoring tech. Gross profit rose slightly to $1.68M in 2026-Q1. The company aims to cut losses but is behind. Partnership expansion supports future growth.
Nuwellis lost $4.57M in operating income in 2026-Q1. Revenue stayed flat at $2.4M after acquisition. The stock plunged 65% on a $6M share offering. Leadership changes and board resignations show instability.
The market prices in about 2% revenue growth and ongoing losses. Our fair value is near $19.74, but the stock trades 84% below consensus price.
Breaks if: Gross profit falls below $1.68M next year
Breaks if: Operating loss worsens beyond -$4.57M next year
No further partnership expansion or partnership losses
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a speculative growth opportunity. The current thesis state reflects uncertainty due to recent weak financial performance and high volatility in management execution.
The market seems to have priced in a level of fragility, reflecting a cheap valuation compared to peers. However, the expectations gap indicates that the market anticipates challenges ahead, particularly in terms of earnings performance.
Fundamentals may continue to struggle in the near term, given the high probability of an earnings miss. However, management is making progress on key priorities like growing recurring revenue and improving gross margins, which could support longer-term stability.
The thesis hinges on several factors, including the potential for management to maintain guidance and the overall health of the healthcare sector. Additionally, the performance of larger sector players could influence sentiment and momentum for NUWE.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Revenue growth supports recurring revenue and installed base expansion. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 2% next year
Over the next 1 to 3 years, NUWE's outlook remains uncertain, influenced by both internal execution and external market conditions. Not investment advice.